The ability of tumors to evade detection by the immune system via inducing immunosuppression prompted the therapeutic development of immune checkpoint inhibitors. In our recent review, we discussed findings from preclinical and clinical investigations of these agents utilized in combination with radiation inducing abscopal (systemic) antitumor effects.
Keywords: CTLA4; PD1; PDL1; abscopal effect; antibodies; immune checkpoint inhibitors; radiation therapy.